Epiontis agreed to be acquired by Precision for Medicine to create the first fully integrated immune monitoring and epigenetics technology provider in the precision medicine space, providing comprehensive solutions to help immuno-oncology and autoimmune drug companies bring effective therapies to market faster.
Read more about Precision for Medicine


A novel epigenetic assay for follicular T helper cells (Tfh cells) was validated and is now offered for service testing.


Epigenetic assays for Treg and T cells are adapted to allow immune cell monitoring in samples derived from fixed (e.g. paraffin embedded) tissue samples.


Epiontis has provided immune cell monitoring for more than 20 clinical trials and has served six out of the twelve largest pharmaceutical companies.


An epigenetic assay that monitors Th17 cells was developed and validated. Epiontis now offers a portfolio of 12 immune cell monitoring assays.


Novel uses for the Treg assay were demonstrated in five additional publications in the year 2012 by Epiontis and collaborators.


The German Accreditation Body attests that Epiontis is competent under the terms of DIN EN ISO/IEC 17025:2005 to carry out tests in medical laboratory testing in studies and clinical monitoring.


In the journals Epigenetics and Blood, Epiontis publishes results for novel epigenetic assays that monitor T cells and CCR6 positive cells, respectively. In addition, a novel assay format is developed and presented.


Until the end of 2010, Epiontis successfully delivered results to at least 11 pharmaceutical and biotech companies. In addition, more than 20 pilot studies for corporate and academic customers were conducted.


Epiontis developed and validated five novel epigenetic assays for immune cells and now offers a portfolio of six immune monitoring assays.


Together with collaborators, four additional scientific reports relating to the Treg assay were published in 2009 by Epiontis scientists in renowned journals including Blood, Cancer Research and Journal of European Immunology.


Epiontis publishes a key paper further describing the Epiontis Treg Assay and outlining the use of the assay in several indications.


Epiontis was awarded a business innovation grant by Zukunftsfonds Berlin for 2.1 mil. Euro over a period of three years, which will be used to broaden Epiontis' development pipeline in collaboration with the Charite Clinic in Berlin.


Epiontis publishes results describing the development of the epigenetic Treg Assay, a novel tool to measure suppressive immune cells with fields of use in cancer, autoimmune diseases and immunotherapy.

10/2005 to 06/2007

Epiontis successfully completed a collaboration with Genzyme Corp. for the development of a methylation fingerprint-based assay for the quality control process of Carticel, an autologous chondrocyte cell therapy product.


Epiontis was founded by its management team.


Sven Olek, Founder and CEO of Epiontis, co-authors the patent outlining a novel molecular cell identification technology that forms the basis of the intellectual property of Epiontis.  

  1. Privacy Statement: Your phone number or email address will be exclusively used to contact you and will not be given to any third party.
  2. I hereby give my consent to processing of my personal data as described in the Privacy Policy. I acknowledge that the consent is given voluntarily and may be withdrawn at any time by notification per Email (info@epiontis.com).